RUNX3 and neoplasm: Early in 2009, Ogino et al. found that stages I-IV CRC patients who had CIMP-high tumour (defined as ≥6 of the 8 promoters positive: CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) experienced significantly lower cancer-specific mortality [38].